Bo Chen
Impact in
- Oncology top 5%
- Cancer Immunotherapy and Biomarkers
- Inflammatory Biomarkers in Disease Prognosis
- Cancer Research top 5%
- Cancer-related molecular mechanisms research
Papers in
- Oncology 52
- Cancer Immunotherapy and Biomarkers 11
- Pancreatic and Hepatic Oncology Research 8
- HER2/EGFR in Cancer Research 7
- Lung Cancer Research Studies 6
-
- RNA modifications and cancer 8
- Co-authors
- Guochun Zhang (20 shared papers)Danian Dai (11 shared papers)Ning Liao (16 shared papers)Xu‐Guang Guo (1 shared paper)Zhenwei Liu (1 shared paper)Guoqiang Wang (1 shared paper)Shahzad Akbar Khan (1 shared paper)Yangchao Chen (1 shared paper)
- Journals
- Frontiers in Oncology (7 papers)Journal of Clinical Oncology (4 papers)Aging (4 papers)Journal of Cellular and Molecular Medicine (4 papers)PLoS ONE (3 papers)
- Partner nations
- ChinaUnited StatesCanada
In The Last Decade
Bo Chen
112 papers receiving 2.0k citations
Bo Chen's Hit Papers
Peers
Comparison fields: 5 of 115
- Oncology 610
- Cancer Research 294
- Infectious Diseases 214
- Molecular Biology 735
- Pulmonary and Respiratory Medicine 310
Countries citing papers authored by Bo Chen
This map shows the geographic impact of Bo Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bo Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bo Chen more than expected).
Fields of papers citing papers by Bo Chen
This network shows the impact of papers produced by Bo Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bo Chen. The network helps show where Bo Chen may publish in the future.
Co-authors
The 25 scholars most cited alongside Bo Chen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 120 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2020 | 293 | |
| 2 | 2007 | 157 | |
| 3 | 2015 | 96 | |
| 4 | 2022 | 95 | |
| 5 | 2019 | 85 | |
| 6 | crVDAC3 alleviates ferroptosis by impeding HSPB1 ubiquitination and confers trastuzumab deruxtecan resistance in HER2-low breast cancer Hit paper breakdown → | 2024 | 51 |
| 7 | 2019 | 48 | |
| 8 | 2015 | 45 | |
| 9 | 2020 | 43 | |
| 10 | 2018 | 40 | |
| 11 | 2020 | 37 | |
| 12 | 2016 | 36 | |
| 13 | 2017 | 36 | |
| 14 | 2020 | 33 | |
| 15 | 2021 | 31 | |
| 16 | 2021 | 29 | |
| 17 | 2012 | 29 | |
| 18 | 2023 | 27 | |
| 19 | 2020 | 27 | |
| 20 | 2012 | 26 |
About Bo Chen
Bo Chen is a scholar working on Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Cancer Research and Immunology, having authored 120 papers that have together received 2.0k indexed citations. Recurring topics across this work include Ferroptosis and cancer prognosis (11 papers), Cancer Immunotherapy and Biomarkers (11 papers), Cancer Genomics and Diagnostics (9 papers), Pancreatic and Hepatic Oncology Research (8 papers), RNA modifications and cancer (8 papers), HER2/EGFR in Cancer Research (7 papers), Lung Cancer Research Studies (6 papers) and Cancer-related molecular mechanisms research (5 papers). The work is most often cited by research in Oncology (610 citations), Cancer Research (294 citations), Infectious Diseases (214 citations), Molecular Biology (735 citations) and Pulmonary and Respiratory Medicine (310 citations). Bo Chen has collaborated with scholars based in China, United States and Canada. Frequent co-authors include Guochun Zhang, Danian Dai, Ning Liao, Xu‐Guang Guo, Zhenwei Liu, Guoqiang Wang, Shahzad Akbar Khan, Yangchao Chen, Tianxing Ji and Jianguo Lai. Their work appears in journals such as Frontiers in Oncology, Journal of Clinical Oncology, Aging, Journal of Cellular and Molecular Medicine and PLoS ONE.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.